LivaNova PLC (LIVN) is a publicly traded company in the Healthcare sector, operating within the Medical - Devices industry. The company is headquartered in London, United Kingdom. The current CEO is Vladimir A. Makatsaria.
LIVN has IPO date of 2015-10-19, 2,900 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.55B.
LivaNova PLC is a global medical device company headquartered in London that designs, develops, manufactures, and sells therapeutic solutions across three primary segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment produces heart-lung machines, oxygenators, and perfusion systems for surgical use, while the Neuromodulation segment markets the VNS Therapy System, an implantable device for treating drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea, and is developing the VITARIA System for heart failure treatment. The Advanced Circulatory Support segment provides temporary life support solutions for cardiopulmonary and respiratory support. LivaNova serves hospitals, medical institutions, and healthcare providers worldwide through a network of direct sales representatives and independent distributors, and collaborates with leading organizations such as Verily on clinical research initiatives.
